It is the first cause of blindness in the Western world, with an estimation of up to 18.6 million people being affected by the blinding stages of the disease by 2040 worldwide [1], though a consistent decline in blindness secondary to AMD has been observed from 1990 to 2020 thanks to the introduction of anti-vascular endothelial growth factor agents (VEGF) [2]. Here, VEGFA is linked to blindness (disorder).